等待开盘 10-06 09:30:00 美东时间
+0.090
+4.36%
Immuron ( ($IMRN) ) has shared an announcement. On October 3, 2025, Immuron Lim...
10-03 22:17
US Tariffs: Immuron does not anticipate any material impact from the recently announced US tariffs on pharmaceutical productsTravelan® Clinical Study: Topline results from the Travelan® clinical study conducted
10-02 18:38
Immuron Limited ( ($AU:IMC) ) just unveiled an update. Immuron Limited announce...
10-02 07:54
Immuron ( ($IMRN) ) has issued an announcement. On September 30, 2025, Immuron ...
09-30 20:29
Immunot Limited has partnered with InvestorHub to launch an interactive investor hub, enhancing communication with shareholders and investors. The platform will feature regular updates, including videos, educational materials, and research. CEO Steven Lydeamore highlighted upcoming milestones: FDA submission and approval of IMM-529 IND and clinical trial results for Travelan®. The company focuses on developing orally administered antibodies for i...
08-27 02:29
Immuron Limited ( ($AU:IMC) ) has issued an announcement. Immuron Limited has p...
08-26 13:57
Immuron Limited ( ($AU:IMC) ) has issued an announcement. Immuron Limited annou...
07-25 08:57
Shares of Interactive Brokers Group, Inc. (NASDAQ:IBKR) rose sharply in pre-mar...
07-18 18:34
GlobalAnnual sales AUD$7.3 million up 49% on prior yearJune 2025 Quarter AUD$2.0 million up 55% on prior yearAustralia Annual sales AUD$5.2 million up 40% on prior yearJune 2025 Quarter AUD$1.5 million up 58% on
07-17 18:07
Immuron Limited reported FY25 sales growth of 49% to $7.3M AUD, driven by strong performance in Australia (40% growth) and North America (76% growth). Travelan® sales exceeded projections, benefiting from increased consumer engagement and targeted marketing efforts, particularly on Amazon in the U.S. and expanding distribution in Canada. --- **总结内容:** Immuron Limited FY25销售额增长49%至730万澳元,澳大利亚市场增长40%,北美市场增长76%。Travelan®销售额超出预期,得益于消费者参与度提高和针对性营销,...
07-17 10:00